



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

# Preamanalytical Considerations for Joint Fluid Evaluation



Caitlyn R. Martinez, DVM, Kelly S. Santangelo, DVM, PhD\*

## KEYWORDS

- Synovial fluid • Orthopedics • Osteoarthritis • Immune-mediated polyarthropathy
- Septic arthritis

## KEY POINTS

- Synovial fluid analysis is a key component of the minimum database needed to diagnose and manage primary and secondary articular joint disorders.
- Preamanalytical variables can drastically alter samples submitted to veterinary laboratories for evaluation and it is considered the stage at which most laboratory error occurs.
- Common indications for the collection of synovial fluid include orthopedic lameness; abnormal limb function or gait; articular pain and/or distention; fever of unknown origin; or widespread pain, stiffness, or difficulty moving.
- The gross characteristics of synovial fluid yield important information as to the quality and pathology of the joint and should be noted at the time of sample collection.
- When arthrocentesis yields small sample volumes, cytologic evaluation of direct smears offers the most clinically relevant information available from synovial fluid.

## INTRODUCTION

In concert with clinical history, physical examination, imaging modalities, and other clinical pathology findings, synovial fluid analysis is a key component of the minimum database needed to diagnose and manage primary and secondary articular joint disorders. The preanalytical phase of synovial fluid evaluation encompasses the steps from initial sample collection through final arrival and accessioning at the diagnostic laboratory. Unfortunately, preanalytical variables can drastically alter samples submitted for evaluation to veterinary laboratories and it is considered the stage at which most laboratory error occurs.<sup>1</sup> Specific variables that may influence the interpretation

---

The authors have nothing to disclose.

Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 1644 Campus Delivery, Fort Collins, CO 80523, USA

\* Corresponding author.

E-mail address: [kelly.santangelo@colostate.edu](mailto:kelly.santangelo@colostate.edu)

Vet Clin Small Anim 47 (2017) 111–122

<http://dx.doi.org/10.1016/j.cvsm.2016.07.007>

0195-5616/17/© 2016 Elsevier Inc. All rights reserved.

[vetsmall.theclinics.com](http://vetsmall.theclinics.com)

of joint fluid mostly involve technical factors, such as selection of collection materials, evidence of blood contamination, and specimen handling. Other considerations that should be included with sample submission include the location that was aspirated, the signalment and presenting signs of the animal, and current medications being administered. With consistent preanalytical quality control and reporting of specimens, downstream clinical decision making and management of patients can be accelerated and improved. General practitioners should always feel comfortable contacting a diagnostic laboratory for specific information regarding sample acquisition, processing, and submission.<sup>2,3</sup>

## ORIGINS AND CHARACTERISTICS OF SYNOVIAL FLUID

Joints are the points of interaction and movement between 2 adjacent bones. Hyaline cartilage overlays the subchondral bone and is the contact surface. Chondrocytes within the articular cartilage produce the proteoglycans present in the cartilage. This articular space is enclosed by a joint capsule. The joint capsule is composed of a tough, fibrous external surface, a vascular subsynovial layer, and the lining synovial surface. The synovium is thin and contains 2 types of cells, or synoviocytes. These cells are either phagocytic and thus similar to macrophages (type A synoviocytes), or they produce hyaluronic acid, a glycosaminoglycan (type B synoviocytes).<sup>4</sup> Both types of synoviocytes can be visualized on cytologic preparations of synovial fluid, but are typically difficult to differentiate in normal joints and are classified together as large mononuclear cells.

Synovial fluid from a nondiseased joint is an ultrafiltrate of plasma that is modified by secretion of hyaluronic acid, glycoproteins, and other macromolecules. Smaller molecules, such as glucose and electrolytes, can occur in synovial fluid in concentrations equivalent to those in plasma. Proteins from plasma, however, are included in this synovial dialysate only to a limited extent. Synovial fluid serves 2 major purposes. First, it provides a source of nutrition and waste removal from articular chondrocytes. Second, joint fluid lubricates opposing articular cartilage surfaces, limiting friction and wear during contact. Although hyaluronic acid has some lubricating properties, glycoproteins are the primary source of reduced friction during joint motion.

When the components of the joint become diseased, injured, and/or inflamed, pathology is frequently reflected by changes within synovial fluid. Evidence of abnormal conditions include joint effusion with decreased viscosity and increased protein content, increased numbers of inflammatory cells, changes in the percentages of different cell types present, and intra-articular hemorrhage.

## INDICATIONS FOR COLLECTION OF SYNOVIAL FLUID

Synovial fluid analysis is a critical aspect of the workup for an animal exhibiting joint issues, whether these concerns are primary maladies localized to one or more limbs or reflect the secondary manifestation of a systemic condition. Importantly, these data must be integrated with other clinical and laboratory findings, including culture, serology, antinuclear antibody titer, and rheumatoid factor titer. Common indications for the collection of synovial fluid include orthopedic lameness, abnormal limb function or gait, articular pain and/or distention; fever of unknown origin; or widespread pain, stiffness, or difficulty moving.<sup>5</sup>

Typical characteristics of synovial fluid from dogs and cats are presented in **Table 1**. Normal synovial fluid is light yellow and clear, with no observable particular material. The volume that can be aspirated depends on the joint being sampled and the condition of the joint. For most large breed dogs, less than 0.5 mL of synovial fluid is

Species	TNCC (Cells/ $\mu$ L)	% Neutrophils	Expected Volume, mL	Gross Appearance
Dog	$\leq 2900$	$\leq 12$	$\leq 0.5$	Light yellow
Cat	$\leq 1134$	$\leq 39$	$\leq 0.25$	Clear Highly viscous Thixotropic

Abbreviation: TNCC, total nucleated cell count.

Data from Refs.<sup>11,18,19,37</sup>

expected from most joints. Up to 1 mL of fluid can be collected from stifle joints,<sup>6</sup> and the volume of joint fluid obtained from dogs with hip dysplasia can range from 2 to 6 mL.<sup>7</sup> Joints from small dogs and cats do not typically yield more than 0.25 mL of synovial fluid.

## RECOMMENDATIONS FOR SAMPLE COLLECTION

### Collection Sites

Routine sterile technique should be followed for all arthrocentesis procedures, including the clipping of fur and thorough scrubbing of the area. The clinician should judge the amount of restraint and sedation or anesthesia needed to accomplish joint fluid collection in the absence of complications. Ultrasonography is frequently used and recommended for guiding arthrocentesis procedures and characterizing joint lesions in humans.<sup>8,9</sup> Unwanted events include blood contamination, retrieving an insufficient volume of synovial fluid, scratching articular surfaces, or damaging local blood vessels, nerves, or the synovial membrane. Before removing the needle from the joint, the plunger of the syringe should be released to eliminate negative pressure.

Brief descriptions of recommended approaches to synovial fluid collection from articular joints are provided in [Table 2](#). When noninfectious polyarthritis is a differential diagnosis, it is recommended that arthrocentesis be performed on multiple joints, specifically the carpi, tarsi, and stifle joints. Clinical signs commonly associated with polyarthritis include leg-shifting lameness, fever of unknown origin, and joint pain. Of note, however, one retrospective study documented that polyarthritis also can present simply as difficulty walking, without any other significant findings.<sup>10</sup>

### Collection Materials

#### Needles and syringes

Sterile disposable 0.75-inch to 1-inch, 22-gauge or 25-gauge hypodermic needles connected to 3-mL to 6-mL syringes are recommended. Some researchers prefer a 25-gauge needle attached to a 1-mL or 3-mL syringe for feline arthrocentesis, as increased blood contamination is noted with larger-bore needles.<sup>11</sup> In larger-breed dogs, sampling of the shoulder or elbow joint may necessitate a 1.5-inch needle, whereas the hip may require a 3.0-inch spinal needle.

#### Tube selection

When inflamed synovial membranes have increased vascular permeability, this allows increased proteins, such as fibrinogen, into joint fluid. This often results in clotting of synovial fluid samples. Clotting can also occur with significant hemorrhage or blood contamination. Given this, it is recommended to aliquot a portion of the sample into an ethylenediaminetetraacetic acid (EDTA) tube to prevent coagulation and allow for additional analyses.<sup>5</sup> The smallest EDTA blood tube available should be used to avoid

<b>Table 2</b>			
<b>Suggested positioning and entry for arthrocentesis of common joints</b>			
<b>Articular</b>			
<b>Joint</b>	<b>Position</b>	<b>Needle Entry</b>	<b>Needle Advancement</b>
Stifle	Flexed	Lateral to patellar tendon and distal to patella	Needle is advanced in a medial and proximal direction, pointing toward the medial condyle of the femur
Hip	Femur is abducted and leg extended caudally	Cranial to the greater trochanter of the femur	Needle is inserted caudal and distal to the joint
Shoulder	Neutral to flexed	Distal to the acromion of the scapula and caudal to the greater tubercles of the humerus	Needle is directed medially toward the greater tubercle and just distal to the supraglenoid tubercle of the scapula
Elbow	Extended or flexed	Extended: Medial to the lateral epicondyle of the humerus and lateral to the olecranon Flexed: Proximal to the olecranon and medial to the lateral epicondylar crest	Needle is inserted parallel to the olecranon and the long axis of the ulna
Carpus	Flexed	Antebrachio-carpal joint: Between the distal radius and proximal radial carpal bone Middle carpal joint: Distal portion of the radial carpal bone and the second and third carpal bones	Needle is introduced from the dorsal aspect, just medial of center, and inserted perpendicular to joint
Tarsus	Extended or flexed	Extended (caudal approach): Medial or lateral to the calcaneus Flexed (cranial approach): Space palpated between tibia and talus bones, just lateral to the tendon bundle	Extended: Needle is advanced with a cranial and slightly plantar path Flexed: Needle is inserted perpendicular to palpated space

erroneous results due to sample dilution from excess anticoagulant. If small tubes are not available, then excess EDTA can be decanted from the vessel before adding the sample.

In contrast, EDTA can cause disruption of hyaluronic acid. Therefore, it is not recommended to evaluate synovial fluid viscosity or mucin clot formation from EDTA samples. When this is desired, sample should be provided in a tube that does not contain this particular anticoagulant, such as a red top tube or a heparin tube.<sup>12</sup>

For samples that are to be cultured, fluid should be left in the sterile syringe and/or placed into an aerobic culturette or blood culture tube. A red top tube also may be used for this purpose if sterility can be maintained. To increase the likelihood of a positive culture, it is recommended to place the synovial fluid sample in blood culture media if available. Synovial membrane biopsy for culture is not recommended, as it has been shown to be less successful at yielding positive culture results than synovial fluid culture. Additionally, synovial membrane biopsy is considerably more invasive and traumatic than arthrocentesis.<sup>13</sup>

### ***Sequential Arthrocentesis***

---

Sequential arthrocentesis and synovial fluid analysis is often performed as part of the therapeutic monitoring of immune-mediated polyarthritis. It is recognized that arthrocentesis is a traumatic procedure and may elicit mild mononuclear inflammation. However, one study performed in healthy dogs showed that synovial fluid collection every 3 weeks did not result in differing cell counts or percentages.<sup>14</sup> Thus, repeated collections using this length of time are considered less likely to be clinically significant or obscure evidence of a therapeutic response.

### **VISUAL ASSESSMENT OF COLLECTED SAMPLE**

The gross characteristics of synovial fluid yield important information as to the quality and pathology of the joint and should be noted at the time of sample collection. Even when limited sample is available and only a direct smear can be prepared, it is still possible to evaluate the approximate volume, color, viscosity, and turbidity of synovial fluid as the sample is aspirated, expelled onto a slide, and smeared.<sup>15</sup> Homogeneously red or red-tinged fluid indicates hemorrhage in the joint, which is usually associated with trauma or inflammation. This should be differentiated from blood contamination, as discussed later in this article. Xanthochromia, which imparts a yellow-orange discoloration to joint fluid due to hemoglobin breakdown, may be seen following the resolution of hemorrhage. Overt sediment and/or white or light yellow coloration indicates either an increase in the nucleated cell count, usually due to inflammation, infection, or neoplasia, or the presence of crystals. Increased turbidity results from suspended particulate matter, which may be related to red or white cells, fibrin, bacteria/organisms, or, less commonly, crystals. It is rare for crystals or neoplastic cells, alone, to cause changes in color or turbidity.<sup>16</sup>

It is important to recognize that normal synovial fluid does not clot in a tube or syringe, but instead forms a gel. Distinction of these 2 states can be accomplished by agitation of the sample, which will cause the gel, but not a clot, to return to its fluid state. This reversible fluid-gel phenomenon is called thixotropism.

### **VALUE OF DIRECT SMEAR PREPARATION**

Small animal arthrocentesis often yields limited sample volume. In such scenarios, it is commonly advised that cytologic evaluation of direct smears offers the most clinically relevant information available from synovial fluid.<sup>15,17,18</sup> Given the viscosity of joint fluid, a squash or compression preparation is typically used to generate direct smears. It is recommended that direct smears be made immediately following sample collection and before any additional processing. This prevents artifacts or misinterpretations due to sample aging, concentration, dilution, or contamination.<sup>2,3</sup> A rough estimation of total nucleated cell count (TNCC), differential counts, characterization of any unusual cells that may be present, as well as a subjective assessment of the proteoglycan background, are all possible to evaluate from a direct smear, alone. Indeed, direct smears are often preferred over cytocentrifuge-prepared slides for differential cell counts, as some researchers feel that the latter may not provide an accurate representation of cell proportions and that the morphology of the cells may be altered during centrifugation.<sup>2,19</sup> In particular, a diagnosis of suppurative inflammation can be reliably made using direct smears.<sup>20</sup> If sample quantity allows, recommended additional tests include TNCC (obtained via automated or hemocytometer methods), total protein, and mucin clot test. If there is concern for bacterial arthritis, 2 to 3 drops of synovial fluid for culture and sensitivity can be placed into a culturette.

One issue with direct smears is that highly viscous synovial fluid often yields thick preparations with cell clumping and severely rounded up cells that cannot be easily identified or counted. This tends not to be a problem, however, when the joint is diseased and the synovial fluid is dilute. To address thick samples, hyaluronidase can be added to synovial fluid before slide preparation. It is recommended that 150 IU/mL hyaluronidase be mixed with an equal volume of joint fluid and incubated for several minutes before direct smear slide preparation.<sup>19</sup> When used, it is suggested to use gentle smearing technique, as the hyaluronidase treatment tends to cause the cells to become more fragile.

Direct smears should always be evaluated before submission to ensure adequate cellularity and distribution of synovial fluid. However, certain caveats should be emphasized, even to pathologists. First, it has been shown that the estimation of total cell count on direct smears varies from clinician to clinician and can often overestimate true cell numbers.<sup>20</sup> Further, distinguishing between normal synovial fluid and synovial fluid reflective of degenerative joint disease or osteoarthritis is not consistent using direct smears. Finally, direct smears should not be used as the sole indication of disease progression or evidence for therapeutic efficacy.<sup>20</sup>

## KEY INFORMATION TO PROVIDE WITH SAMPLE SUBMISSION

### *Signalment*

---

The species, age, breed, and gender of an animal can provide key information for prioritizing potential diagnoses. For example, synovial cell sarcoma is a rare tumor in animals, but occurs far more commonly in dogs than cats.<sup>21</sup> Clinical signs of polyarthritid syndrome in akitas typically appear before 8 months of age.<sup>22</sup> Bernese mountain dogs have the highest prevalence for the systemic form of histiocytic sarcoma; however, skeletal manifestation of this disease occur far more commonly in rottweilers and golden retrievers.<sup>23</sup>

### *Pertinent Clinical History*

---

Patient history can help characterize the disease process and narrow the differential list. For example, bacterial septic arthritis may develop following articular surgery, local trauma and direct inoculation, extension from regional infections, or hematogenous spread.<sup>24</sup> In one case, septic arthritis occurred secondary to a migrating porcupine quill, which had been reported to travel 10 inches under the skin.<sup>25</sup> Bacterial septic arthritis is often thought to present as acute, severe lameness but it may also develop as chronic, mild pain without significant orthopedic impairment.<sup>26</sup> Immune-mediated polyarthropathy has been associated with a variety of processes, such as vaccine reactions, drug reactions, existing neoplasia, gastrointestinal disease, and idiopathic causes.<sup>27</sup> Suspicion for foreign body reactions, with or without secondary infection, also relies on a complete discussion of pertinent events, even if these events are not recent. For instance, onset of severe arthropathy was reported in a dog 21 months after being shot in the elbow with a lead bullet.<sup>28</sup> Interestingly, the metallic fragments did not mechanically interfere with joint motion.

### *Location(s) Aspirated*

---

Noting the joints affected and the joints aspirated can help delineate the full extent of disease and place emphasis on one diagnosis over another. For instance, the inflammation associated with immune-mediated polyarthropathy is thought to be elicited by complement activation following antigen-antibody complex deposition within the

synovium of multiple joints. Of note, lesions are most commonly observed in smaller joints, such as the carpi and tarsi.<sup>29</sup>

### **Current Medications and Nutritional Supplements**

---

Administration of any medication should be provided on the submission form, especially if that treatment is directed at a disorder on the differential list. This includes systemic medications, as well as local, regional, and topical drugs. Of note, it is well-demonstrated that the application of nonsteroidal anti-inflammatory drugs on the skin can penetrate local tissues into the synovial fluid.<sup>30</sup>

It also may be pertinent to disclose the use of nutraceuticals and other supplements. Clinical trials that support the use of glucosamine, chondroitin sulfate, P54FP (a turmeric extract), omega-3 fatty acids, *Boswellia serrata* (a tree extract), and avocado-soybean unsaponifiable extracts in dogs with osteoarthritis, after surgery or trauma, and for prophylactic measures have been reported.<sup>31</sup> However, these studies are limited in number and there remains a need for additional randomized controlled clinical trials. Further, despite the perception that joint health products are safe based on high LD50 values and an absence of persistent adverse effects, veterinarians should be aware that contamination issues, including toxins, pesticides, and heavy metals, and metabolic concerns, particularly the use of glucosamine in individuals with type 2 diabetes, are being addressed in human and animal studies.<sup>31</sup>

### **Blood Contamination**

---

Careful observation during arthrocentesis may demonstrate a flash of blood in the sample, indicative of blood contamination. Alternatively, a diffusely bloody sample may indicate that the sample is associated with true hemorrhage. As these separate scenarios may appear similar following shipment and arrival to the laboratory, it is important that differentiation of the 2 be documented during sample submission.<sup>5</sup>

## **SHIPPING RECOMMENDATIONS**

Synovial fluid supplied in tubes or syringes can be stored or shipped at 4°C for up to 24 hours without significant loss of cytologic integrity. Therefore, it is recommended that samples being sent to laboratories be packaged with cold packs and shipped overnight to maintain sample value.<sup>32</sup> When providing direct smears, ensure that these slides are completely dry before packaging and kept away from exposure to formalin fumes. Do not refrigerate slides, as subsequent condensation may result in cell lysis.

## **DIFFERENTIAL DIAGNOSES**

Several excellent textbook and review articles are available that discuss approaches to the analytical phase of synovial fluid evaluation. This stage includes cytologic evaluation of the sample, as well as a description of its appearance, protein content, viscosity, mucin clot test, nucleated cell count, and differential. In particular, the reader is referred to a wonderfully thorough article by MacWilliams and Fredericks, published by this compendium in 2003.<sup>16</sup>

Briefly, during the analytical phase of cytologic examination, cells will be differentially counted as small mononuclear, large mononuclear, or neutrophils. Cells will be further characterized by nuclear morphology (such as degeneration in neutrophils) and degree of vacuolization (an indication of activation in macrophages), as well as any other significant features.<sup>29</sup> Other cells that may be present will be described and interpreted. The sample will be carefully screened for the presence of any infectious agents. Cells are typically found on an eosinophilic, finely granular background



Table 3

Three general categories of arthropathies in veterinary medicine and associated differential diagnoses

Hemarthritis		Noninflammatory Arthropathy	
Red to xanthochromic appearance with increased protein, decreased viscosity, and normal to poor mucin clot. TNCC will be increased in proportion to the amount of blood. May see hemosiderin, hematoidin, and erythrophagia. <sup>19,29,38</sup>		Clear appearance with normal to decreased protein and viscosity, normal to poor mucin clot. TNCC will be normal to moderately increased with $\geq 90\%$ small and large mononuclear cells. Cells may have increased vacuolization. <sup>29,38</sup>	
Coagulopathy		Degenerative joint disease	
Joint trauma		Joint trauma (ie, cranial cruciate ligament rupture)	
Some neoplasms		Some neoplasms	
Inflammatory Arthropathy			
Cloudy appearance with normal to increased protein, normal to decreased viscosity, and fair to poor mucin clot. TNCC will be mildly to markedly increased with $>10\%$ – $100\%$ neutrophils. <sup>38</sup> Some specific processes may be predominantly mononuclear or eosinophilic inflammation rather than suppurative.			
<i>Infectious</i>	<i>Erosive</i>	<i>Nonerosive</i>	<i>Others</i>
May see degenerate neutrophils. May see infectious organisms. Monoarticular or polyarticular.	Radiographic evidence of articular erosion. Frequently polyarticular.	Erosive and infectious disease have been ruled out. Frequently polyarticular.	May see neoplastic cells or crystals on cytology. Frequently induce an inflammatory response.
Bacteria (cocci, rods, L-forms) <sup>24–26,39</sup>	Rheumatoid arthritis <sup>54</sup>	Systemic lupus erythematosus <sup>27</sup>	Joint trauma <sup>28</sup>
Fungi ( <i>Coccidioides</i> , <i>Aspergillus</i> , <i>Histoplasma</i> , <i>Blastomyces</i> , <i>Cryptococcus</i> ) <sup>40–44</sup>	Greyhound erosive polyarthritis <sup>55</sup>	Idiopathic polyarthritis <sup>27</sup>	Neoplasia
<i>Rickettsia/Ehrlichia</i> spp. <sup>34–36</sup>	Juvenile-onset polyarthritis syndrome in akitas <sup>22</sup>	Idiopathic localized eosinophilic arthritis (cat) <sup>59</sup>	Primary
<i>Borrelia burgdorferi</i> <sup>27,45</sup>	Shar pei fever <sup>56</sup>	Drug-induced polyarthritis <sup>60</sup>	Histiocytic sarcoma <sup>23,64–67</sup>
<i>Mycoplasma</i> spp <sup>46,47</sup>	Chronic progressive polyarthritis (cat) <sup>57,58</sup>	Lymphoplasmacytic synovitis <sup>61</sup>	Synovial cell sarcoma <sup>21,67,68</sup>
<i>Leishmania</i> spp <sup>48</sup>		Postvaccinal arthritis <sup>27,62</sup>	Synovial myxoma <sup>67</sup>
West Nile virus (dog) <sup>49</sup>		Polyarthritis polymyositis syndrome <sup>63</sup>	Malignant fibrous histiocytoma <sup>67</sup>
Feline calcivirus <sup>50,51</sup>			Fibrosarcoma <sup>67</sup>
Feline coronavirus (FIP) <sup>52</sup>			Chondrosarcoma <sup>67</sup>
Canine distemper virus <sup>53</sup>			Undifferentiated sarcoma <sup>67</sup>
			Benign giant cell tumor of the tendon sheath <sup>69</sup>
			Lymphoma <sup>70</sup>
			Osteosarcoma <sup>71</sup>
			Hemangioma <sup>72</sup>
			Metastatic
			Transitional cell carcinoma <sup>73</sup>
			Mammary adenocarcinoma <sup>74</sup>
			Bronchiolar-alveolar carcinoma <sup>75</sup>
			Crystal-induced arthritis
			Pseudogout <sup>76</sup>

composed of synovial fluid proteoglycans. Changes in this proteoglycan milieu, such as can occur with dilution, also will be noted and described.

It is important to remember that synovial fluid evaluation cannot be performed in isolation from other diagnostic tests. For example, a presumptive diagnosis of systemic lupus erythematosus requires more than cytologic observation of lupus erythematosus cells and ragocytes. Clinical signs, antinuclear antibody titers, and response to treatment also must be taken into account.<sup>33</sup> In addition, if rickettsial infection is suspected, it is recommended to perform both acute and convalescent serologic titers and polymerase chain reaction tests, as all tests can produce false negatives depending on the specific etiologic agent and stage of infection. Rarely, morulae can be observed in synovial fluid samples but specific identification of the rickettsial agent cannot be confirmed on cytology alone.<sup>34–36</sup> **Table 3** provides a summary of various arthropathies encountered in veterinary medicine.

## REFERENCES

1. Braun JP, Bourges-Abella N, Geffre A, et al. The preanalytic phase in veterinary clinical pathology. *Vet Clin Pathol* 2015;44(1):8–25.
2. Gunn-Christie RG, Flatland B, Friedrichs KR, et al. ASVCP quality assurance guidelines: control of preanalytical, analytical, and postanalytical factors for urinalysis, cytology, and clinical chemistry in veterinary laboratories. *Vet Clin Pathol* 2012;41(1):18–26.
3. Tomlinson L, Boone LI, Ramaiah L, et al. Best practices for veterinary toxicologic clinical pathology, with emphasis on the pharmaceutical and biotechnology industries. *Vet Clin Pathol* 2013;42(3):252–69.
4. Johnston SA. Osteoarthritis: joint anatomy, physiology, and pathobiology. *Vet Clin North Am Small Anim Pract* 1997;27:699–734.
5. Boon GD. Synovial fluid analysis: a guide for small-animal practitioners. *Vet Med* 1997;92:443–51.
6. Dearmin MG, Trumble TN, García A, et al. Chondroprotective effects of zoledronic acid on articular cartilage in dogs with experimentally induced osteoarthritis. *Am J Vet Res* 2014;75(4):329–37.
7. Fujita Y, Hara Y, Nezu Y, et al. Direct and indirect markers of cartilage metabolism in synovial fluid obtained from dogs with hip dysplasia and correlation with clinical and radiographic variables. *Am J Vet Res* 2005;66(12):2028–33.
8. Punzi L, Oliviero F. Arthrocentesis and synovial fluid analysis in clinical practice: value of sonography in difficult cases. *Ann N Y Acad Sci* 2009;1154:152–8.
9. Mach AJ, Adeyiga OB, Di Carlo D. Microfluidic sample preparation for diagnostic cytopathology. *Lab Chip* 2013;13(6):1011–26.
10. Jacques D, Cauzinille L, Bouvy B, et al. A retrospective study of 40 dogs with polyarthritis. *Vet Surg* 2002;31:428–34.
11. Pacchiana PD, Gilley RS, Wallace LJ, et al. Absolute and relative cell counts for synovial fluid from clinically normal shoulder and stifle joints in cats. *J Am Vet Med Assoc* 2004;225(12):1866–70.
12. Ogston AG, Sherman TF. Degradation of the hyaluronic acid complex of synovial fluid by proteolytic enzymes and by ethylenediaminetetra-acetic acid. *Biochem J* 1959;72:301–5.
13. Montgomery RD, Long IR, Milton JL, et al. Comparison of aerobic culturette, synovial membrane biopsy, and blood culture medium in detection of canine bacterial arthritis. *Vet Surg* 1989;18(4):300–3.

14. Berg RIM, Sykes JE, Kass PH, et al. Effect of repeated arthrocentesis on cytologic analysis of synovial fluid in dogs. *J Vet Intern Med* 2009;23:814–7.
15. Pedersen NC. Synovial fluid collection and analysis. *Vet Clin North Am Small Anim Pract* 1978;8(3):495–9.
16. MacWilliams PS, Friedrichs KR. Laboratory evaluation and interpretation of synovial fluid. *Vet Clin North Am Small Anim Pract* 2003;33:153–78.
17. Hardy RM, Wallace LJ. Arthrocentesis and synovial membrane biopsy. *Vet Clin North Am Small Anim Pract* 1974;4(2):449–62.
18. Sawyer DC. Synovial fluid analysis of canine joints. *J Am Vet Med Assoc* 1963;143(6):609–12.
19. Fernandez FR, Grindem CB, Lipowitz AJ, et al. Synovial fluid analysis: preparation of smears for cytologic examination of canine synovial fluid. *J Am Anim Hosp Assoc* 1983;19:727–34.
20. Gibson NR, Carmichael S, Li A, et al. Value of direct smears of synovial fluid in the diagnosis of canine joint disease. *Vet Rec* 1999;144:463–5.
21. Ireifej SJ, Czaya CA, Flanders JA, et al. What is your diagnosis? Large juxta-articular soft tissue mass. *J Am Vet Med Assoc* 2007;230(9):1305–6.
22. Dougherty SA, Center SA, Shaw EE, et al. Juvenile-onset polyarthritis syndrome in akitas. *J Am Vet Med Assoc* 1991;198:849–56.
23. Schultz RM, Puchalski SM, Kent M, et al. Skeletal lesions of histiocytic sarcoma in nineteen dogs. *Vet Radiol Ultrasound* 2007;48(6):539–43.
24. Clements DN, Owen MR, Mosley JR, et al. Retrospective study of bacterial infective arthritis in 31 dogs. *J Small Anim Pract* 2005;46:171–6.
25. Brisson BA, Bersenas S, Etue SM. Ultrasonographic diagnosis of septic arthritis secondary to porcupine quill migration in a dog. *J Am Vet Med Assoc* 2004;224(9):1467–70, 1453–4.
26. Marchevsky AM, Read RA. Bacterial septic arthritis in 19 dogs. *Aust Vet J* 1999;77:233–7.
27. Rondeau MP, Walton RM, Bissett S, et al. Suppurative, nonseptic polyarthropathy in dogs. *J Vet Intern Med* 2005;19:654–62.
28. Barry SL, Lafuente MP, Martinez SA. Arthropathy caused by a lead bullet in a dog. *J Am Vet Med Assoc* 2008;232(6):886–8.
29. Ellison RS. The cytologic examination of synovial fluid. *Semin Vet Med Surg* 1988;3(2):133–9.
30. Mills PC, Magnusson BM, Cross SE. Penetration of a topically applied nonsteroidal anti-inflammatory drug into local tissues and synovial fluid of dogs. *Am J Vet Res* 2005;66(7):1128–32.
31. Oke SL. Indications and contraindications for the use of orally administered joint health products in dogs and cats. *J Am Vet Med Assoc* 2009;234(11):1393–7.
32. Jones STM, Denton J, Holt PJL, et al. Refrigeration preserves synovial fluid cytology. *Ann Rheum Dis* 1993;52:384.
33. Melendez-Lazo A, Fernandez M, Solano-Gallego L, et al. What is your diagnosis? Synovial fluid from a dog. *Vet Clin Pathol* 2015;44(2):329–30.
34. Allison RW, Little SE. Diagnosis of rickettsial diseases in dogs and cats. *Vet Clin Pathol* 2013;42(2):127–44.
35. Gieg J, Rikihisa Y, Wellman M. Diagnosis of *Ehrlichia ewingii* infection by PCR in a puppy from Ohio. *Vet Clin Pathol* 2009;38(3):406–10.
36. Goodman RA, Hawkins EC, Olby NJ, et al. Molecular identification of *Ehrlichia ewingii* infection in dogs: 15 cases (1997-2001). *J Am Vet Med Assoc* 2003;222(8):1102–7.

37. Atilola MAO, Lumsden JH, Rooke F. A comparison of manual and electronic counting for total nucleated cell counts on synovial fluid from canine stifle joints. *Can J Vet Res* 1986;50:282–4.
38. Barger AM. Musculoskeletal system. In: Raskin RE, Meyer DJ, editors. *Canine and feline cytology: a color atlas and interpretation guide*. 3rd edition. St Louis (MO): Elsevier; 2016. p. 353–68.
39. Carro T, Pedersen NC, Beaman BL, et al. Subcutaneous abscesses and arthritis caused by a probable bacterial L-form in cats. *J Am Vet Med Assoc* 1989;194(11):1583–8.
40. Huss B, Collier L, Collins B, et al. Polyarthropathy and chorioretinitis with retinal detachment in a dog with systemic histoplasmosis. *J Am Anim Hosp Assoc* 1994;30:217–24.
41. Oxenford C, Middleton D. Osteomyelitis and arthritis associated with *Aspergillus fumigatus* in a dog. *Aust Vet J* 1986;63:59–61.
42. Johnson LR, Herrgesell EJ, Davidson AP, et al. Clinical, clinicopathologic, and radiographic findings in dogs with coccidioidomycosis: 24 cases (1995-2000). *J Am Vet Med Assoc* 2003;222(4):461–6.
43. Saito M, Sharp NJH, Munana K, et al. CT findings of intracranial blastomycosis in a dog. *Vet Radiol Ultrasound* 2002;43(1):16–21.
44. Headley SA, Mota FCD, Lindsay S, et al. *Cryptococcus neoformans* var. *grubii*-induced arthritis with encephalitic dissemination in a dog and review of published literature. *Mycopathologia* 2016;181:1–7.
45. Kornblatt AN, Urband PH, Steere AC. Arthritis caused by *Borrelia burgdorferi* in dogs. *J Am Vet Med Assoc* 1985;186(9):960–4.
46. Liehmann L, Degasperi B, Sperser J, et al. *Mycoplasma felis* arthritis in two cats. *J Small Anim Pract* 2006;47(8):476–9.
47. Barton MD, Ireland L, Kirschner JL, et al. Isolation of *Mycoplasma spumans* from polyarthritis in a greyhound. *Aust Vet J* 1985;62(6):206–7.
48. Santos M, Marcos R, Assunção M, et al. Polyarthritis associated with visceral leishmaniasis in a juvenile dog. *Vet Parasitol* 2006;141:340–4.
49. Cannon AB, Luff JA, Brault AC, et al. Acute encephalitis, polyarthritis, and myocarditis associated with West Nile virus infection in a dog. *J Vet Intern Med* 2006;20:1219–23.
50. Dawson S, Bennett D, Carter SD, et al. Acute arthritis of cats associated with feline calicivirus infection. *Res Vet Sci* 1994;56(2):133–43.
51. Levy J, Marsh A. Isolation of calicivirus from the joint of a kitten with arthritis. *J Am Vet Med Assoc* 1992;201:753–5.
52. Pedersen NC. A review of feline infectious peritonitis virus infection: 1963-2008. *J Feline Med Surg* 2009;11:225–58.
53. May C, Carter SD, Bell SC, et al. Immune responses to canine distemper virus in joint diseases of dogs. *Rheumatology* 1994;33(1):27–31.
54. Bennett D. Immune-based erosive inflammatory joint disease of the dog: canine rheumatoid arthritis. *J Small Anim Pract* 1987;28(9):799–819.
55. Woodard JC, Riser WH, Bloomberg MS, et al. Erosive polyarthritis in two greyhounds. *J Am Vet Med Assoc* 1991;198:873–6.
56. May C, Hammil J, Bennett D. Chinese shar pei fever syndrome: a preliminary report. *Vet Rec* 1992;131:586–7.
57. Oohashi E, Yamada K, Oohashi M, et al. Chronic progressive polyarthritis in a female cat. *J Vet Med Sci* 2010;72(4):511–4.
58. Pedersen N, Pool R, O'Brien T. Feline chronic progressive polyarthritis. *Am J Vet Res* 1980;41(4):522–35.

59. Silverstein DC, Almy FS, Zinkl JG, et al. Idiopathic localized eosinophilic synovitis in a cat. *Vet Clin Pathol* 2000;29(3):90–2.
60. Trepanier LA. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. *J Vet Pharmacol Ther* 2004;27:129–38.
61. Erne JB, Goring RL, Kennedy FA, et al. Prevalence of lymphoplasmacytic synovitis in dogs with naturally occurring cranial cruciate ligament rupture. *J Am Vet Med Assoc* 2009;235(4):386–90.
62. Kohn B, Garner M, Lübke S, et al. Polyarthritits following vaccination in four dogs. *Vet Comp Orthop Traumatol* 2003;16(1):6–10.
63. Bennett D, Kelly DF. Immune-based non-erosive inflammatory joint disease of the dog. 2. Polyarthritits/polymyositis syndrome. *J Small Anim Pract* 1987;28(10):891–908.
64. Pereira PD, Santos M, Montenegro L, et al. A femorotibial joint swelling with popliteal lymph node enlargement in a rottweiler. *Vet Clin Pathol* 2006;35(3):335–8.
65. Moore PF. A review of histiocytic diseases of dogs and cats. *Vet Pathol* 2014;51(1):167–84.
66. Pinard J, Wagg CR, Girard C, et al. Histiocytic sarcoma in the tarsus of a cat. *Vet Pathol* 2006;43(6):1014–7.
67. Craig LE, Julian ME, Ferracone JD. The diagnosis and prognosis of synovial tumors in dogs: 35 cases. *Vet Pathol* 2002;39(1):66–73.
68. Lowseth LA, Herbert RA, Muggenburg BA, et al. What is your diagnosis? *Vet Clin Pathol* 1989;18(3):57, 73–4.
69. Campbell MW, Koehler JW, Weiss RC, et al. Cytologic findings from a benign giant cell tumor of the tendon sheath in a dog. *Vet Clin Pathol* 2014;43(2):270–5.
70. Lahmers SM, Mealey KL, Martinez SA, et al. Synovial T-cell lymphoma of the stifle in a dog. *J Am Anim Hosp Assoc* 2002;38(2):165–8.
71. Thamm DH, Mauldin EA, Edinger DT, et al. Primary osteosarcoma of the synovium in a dog. *J Am Anim Hosp Assoc* 2000;36:326–31.
72. Miller MA, Pool RR, Coolman BR. Synovial hemangioma in the stifle joint of a dog. *Vet Pathol* 2007;44(2):240–3.
73. Colledge SL, Raskin RE, Messick JB, et al. Multiple joint metastasis of a transitional cell carcinoma in a dog. *Vet Clin Pathol* 2013;42(2):216–20.
74. Lowseth LA, Gillet NA, Muggenburg BA, et al. What is your diagnosis? *Vet Clin Pathol* 1989;18(4):88–9, 101–2.
75. Meinkoth JH, Rochat MC, Cowell RL. Metastatic carcinoma presenting as hind-limb lameness: diagnosis by synovial fluid cytology. *J Am Anim Hosp Assoc* 1997;33(4):325–8.
76. De Haan JJ, Andreasen CB. Calcium crystal-associated arthropathy (pseudogout) in a dog. *J Am Vet Med Assoc* 1992;200(7):943–6.